Stock comparison
Moderna, Inc. is 17.1x more valuable than Immunovant, Inc. by market capitalization ($105.32 B vs $6.17 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 17.1x more valuable than Immunovant, Inc. by market capitalization ($105.32 B vs $6.17 B).
Market value leader
MRNA
Moderna, Inc. is 17.1x more valuable than Immunovant, Inc. by market capitalization ($105.32 B vs $6.17 B).
Profit leader
IMVT
IMVT: -$505.61M vs MRNA: -$2.82B.
| Metric | IMVT | MRNA |
|---|---|---|
| Market cap | $6.17 B | $105.32 B |
| US-listed rank | #1236 | #145 |
| Revenue (latest FY) | - | $1.94B |
| Net income (latest FY) | -$505.61M | -$2.82B |
| Net margin | - | -145.2% |
| P/E (trailing FY) | - | - |
| SEC filings | 611 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 17.1x more valuable than Immunovant, Inc. by market capitalization ($105.32 B vs $6.17 B).
Full pages: Immunovant, Inc. and Moderna, Inc., or browse the full rankings.